Login / Signup

Scalable Asymmetric Syntheses of Foslevodopa and Foscarbidopa Drug Substances for the Treatment of Parkinson's Disease.

Alexander D HutersJames StambuliRussell C KlixMark A MatulenkoVincent S ChanJustin SimanisDavid R HillRajarathnam E ReddyTimothy B TowneJohn R BellettiniBrian J KoteckiBenoit Cardinal-DavidJianguo JiEric A VoightMinshan ShouSelvakumar BalaramanAbhishek AshokSoma Ghosh
Published in: The Journal of organic chemistry (2021)
Foslevodopa (FLD, levodopa 4'-monophosphate, 3) and foscarbidopa (FCD, carbidopa 4'-monophosphate, 4) were identified as water-soluble prodrugs of levodopa (LD, 1) and carbidopa (CD, 2), respectively, which are useful for the treatment of Parkinson's disease. Herein, we describe asymmetric syntheses of FLD (3) and FCD (4) drug substances and their manufacture at pilot scale. The synthesis of FLD (3) employs a Horner-Wadsworth-Emmons olefination reaction followed by enantioselective hydrogenation of the double bond as key steps to introduce the α-amino acid moiety with the desired stereochemistry. The synthesis of FCD (4) features a Mizoroki-Heck reaction followed by enantioselective hydrazination to install the quaternary chiral center bearing a hydrazine moiety.
Keyphrases
  • water soluble
  • parkinson disease
  • amino acid
  • deep brain stimulation
  • randomized controlled trial
  • emergency department
  • fluorescent probe
  • solid state
  • electronic health record